Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Clin Chest Med. 2010 Mar;31(1):151-63, Table of Contents. doi: 10.1016/j.ccm.2009.08.021.
Lung cancer is the commonest cause of cancer-related mortality throughout the world. Only 25% of patients are diagnosed early and are candidates for surgical resection with curative intent. Many early-stage patients are medically inoperable owing to comorbidities. For these patients, and for selected patients with pulmonary metastases, radiofrequency ablation is a minimally invasive therapeutic alternative. Radiofrequency ablation can be performed percutaneously, under conscious sedation, and as an outpatient or with a short hospital stay. Outcomes are similar or even superior to those obtained with more aggressive procedures, with lower complication rates. Human studies describing the feasibility, safety, and outcomes of radiofrequency ablation for the treatment of primary and secondary lung malignancies are the focus of this article.
肺癌是全球癌症相关死亡的最常见原因。只有 25%的患者被早期诊断,并有机会进行治愈性手术切除。许多早期患者由于合并症而不能接受手术治疗。对于这些患者,以及一些有选择的肺转移患者,射频消融是一种微创治疗选择。射频消融可以在清醒镇静下经皮进行,作为门诊手术或短期住院治疗。其结果与更具侵袭性的手术相似,甚至更优,且并发症发生率更低。本文重点介绍了描述射频消融治疗原发性和继发性肺癌的可行性、安全性和结果的人体研究。